Previous 10 | Next 10 |
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company’s Real World Solutions (RWS) bus...
Oncology trial starts reached historically high levels in 2021, up 56% from 2016 and mostly focused on rare cancer indications A record 30 oncology novel active substances were initially launched globally in 2021, and a total of 159 have been launched since 2012 Oncolo...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022 at 11:30 a.m. ET. A live audio webcast of the...
Guggenheim has initiated coverage of five contract research organizations (CROs) and recommends three -- ICON plc (NASDAQ:ICLR), IQVIA Holdings (NYSE:IQV), and Syneos Health (NASDAQ:SYNH) -- as buys. The firm sees the greatest upside -- 32% -- with ICON (ICLR) based on a target price of $285....
Dan Loeb's 13F portfolio value decreased from $14.33B to $7.68B this quarter. The number of positions decreased from 92 to 75. Third Point added CSX & Alcoa while dropping Accenture and Upstart Holdings. They also increased EQT Corporation and Zendesk while reducing Amazon.com and...
With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Companies that are either benefiting from this environment or that are considered safe heavens posted outsized gains. ...
No Rating Change. Medpace remains an attractive business selling at a discount to its intrinsic value. Management is aggressively repurchasing shares, a signal of confidence and a boost to EPS. For further details see: Medpace Holdings: Update Following Q1 FY2022 Earning...
William von Mueffling's 13F portfolio value decreased this quarter from $15.14B to $14.01B. Cantillon increased IQVIA Holdings, BlackRock, and Armstrong World Industries during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ...
IQVIA has the potential to outperform the market in a higher inflation environment. Significant growth potential with projected 17.72% FCF and 11.68% EBIT CAGR over the next 5 years. Decentralized clinical trials, the emergence of virtual trials, blockchain technologies, AI and ML...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...